Clinical Trial

A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-07; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2026-05-13
Trial Details
NCT Number NCT07227207
Lead Sponsor Tessera Therapeutics, Inc.
Conditions Alpha-1 Antitrypsin Deficiency (AATD)
Enrollment 72 participants
Start Date 2026-04-21
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-10